ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate
Jun 2, 2025
14:00
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
CEO David Chang\ describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on Allogene's 1L consolidation trial in LBCL, and his thoughts on cell therapy for autoimmune diseases.
BiotechTV - News